Completed PHASE2 INTERVENTIONAL 8-arm NCT01231503

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine 257049 When Administered on Different Schedules to Infants in Africa

Sponsor: GlaxoSmithKline

Conditions Malaria

Interventions BCG Engerix-B GSK Biological's Investigational Malaria Vaccine 257049 OPV Rouvax Tritanrix HepB Hib

Updated 9 times since 2017 Last updated: Jul 17, 2018 Started: Jan 13, 2011 Primary completion: Apr 30, 2014 Completion: Dec 23, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Malaria and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2018 — Sep 2018 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — May 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangwe, Blantyre, Malawi